MANNKIND CORP
NASDAQ: MNKD (MannKind Corporation)
Kemas kini terakhir: semalam, 2:41PM3.50
0.00 (0.00%)
| Penutupan Terdahulu | 3.50 |
| Jumlah Dagangan | 2,009,438 |
| Harga / Pendapatan (P/E Ke hadapan) | 26.92 |
| Harga / Jualan (P/S) | 2.78 |
| Julat 52 Minggu |
| Margin Keuntungan | 10.12% |
| Margin Operasi (TTM) | 31.65% |
| EPS Cair (TTM) | 0.100 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 23.80% |
| Nisbah Semasa (MRQ) | 2.36 |
| Aliran Tunai Operasi (OCF TTM) | 29.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 39.45 M |
| Pulangan Atas Aset (ROA TTM) | 10.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | MannKind Corporation | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.6 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | -0.9 |
| Kesihatan Kewangan | 4.1 |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 1.04 |
|
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.86% |
| % Dimiliki oleh Institusi | 58.64% |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |